AbbVie Q3 Earnings: Humira Plunge Overshadows Beat

AbbVie reported third-quarter earnings that beat analyst expectations on both revenue and earnings per share. The company's overall revenue grew, driven by strong performance in newer products like Skyrizi and Rinvoq, which are part of its immunology portfolio.

However, the headline beat was marred by a significant decline in sales of Humira, AbbVie's flagship arthritis drug. In the U.S., Humira sales plummeted 39.9% year-over-year, as biosimilar competition intensified. This decline was somewhat offset by growth in other areas, but it remains a major headwind.

The mixed results led to a neutral sentiment from analysts, with Zacks Rank #4 (Sell) rating suggesting caution. While the company's diversification efforts are paying off, the loss of Humira revenue is a substantial challenge that investors are closely watching.

Humira has been AbbVie's cash cow for years, generating billions in revenue. Its decline due to biosimilar competition is inevitable, but the pace of the drop is critical. A 39.9% decline in the U.S. is steep and raises questions about how quickly newer drugs can fill the gap.

Skyrizi and Rinvoq are growing rapidly, but they may not fully replace Humira's lost sales in the near term. The market is closely watching the trajectory of these newer drugs to gauge AbbVie's future growth. If they can sustain high growth rates, the company could navigate the patent cliff successfully.

Additionally, the Zacks Rank #4 (Sell) rating reflects concerns about near-term performance. Investors should monitor upcoming quarters to see if the growth in new products can outpace the decline in Humira. The stock's valuation and dividend yield may provide some support, but the risk of further downgrades remains.